- Home
- ZGN vs IBRX Comparison
ZGN vs IBRX Comparison
Compare ZGN & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZGN
- IBRX
- Stock Information
- Founded
- ZGN 1910
- IBRX 2014
- Country
- ZGN Italy
- IBRX United States
- Employees
- ZGN N/A
- IBRX N/A
- Industry
- ZGN Apparel
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZGN Consumer Discretionary
- IBRX Health Care
- Exchange
- ZGN Nasdaq
- IBRX Nasdaq
- Market Cap
- ZGN 2.1B
- IBRX 2.3B
- IPO Year
- ZGN N/A
- IBRX N/A
- Fundamental
- Price
- ZGN $10.39
- IBRX $2.58
- Analyst Decision
- ZGN Buy
- IBRX Strong Buy
- Analyst Count
- ZGN 5
- IBRX 6
- Target Price
- ZGN $10.22
- IBRX $9.83
- AVG Volume (30 Days)
- ZGN 852.8K
- IBRX 9.7M
- Earning Date
- ZGN 09-05-2025
- IBRX 11-10-2025
- Dividend Yield
- ZGN 1.34%
- IBRX N/A
- EPS Growth
- ZGN N/A
- IBRX N/A
- EPS
- ZGN 0.43
- IBRX N/A
- Revenue
- ZGN $2,248,050,499.00
- IBRX $56,600,000.00
- Revenue This Year
- ZGN N/A
- IBRX $629.94
- Revenue Next Year
- ZGN $4.50
- IBRX $109.91
- P/E Ratio
- ZGN $23.94
- IBRX N/A
- Revenue Growth
- ZGN N/A
- IBRX 4227.22
- 52 Week Low
- ZGN $6.05
- IBRX $1.83
- 52 Week High
- ZGN $10.70
- IBRX $6.82
- Technical
- Relative Strength Index (RSI)
- ZGN 59.67
- IBRX 54.54
- Support Level
- ZGN $10.09
- IBRX $2.30
- Resistance Level
- ZGN $10.65
- IBRX $2.67
- Average True Range (ATR)
- ZGN 0.43
- IBRX 0.12
- MACD
- ZGN 0.02
- IBRX 0.01
- Stochastic Oscillator
- ZGN 84.95
- IBRX 75.68
About ZGN Ermenegildo Zegna N.V.
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.